London
· Delayed Price · Currency is GBP · Price in USD Cara Therapeutics Company Description
Cara Therapeutics, Inc., a development-stage biopharmaceutical company, focuses on developing and commercializing therapeutics treatment of chronic pruritus in the United States.
The company’s lead product is KORSUVA (difelikefalin) injection for the treatment of moderate-to-severe pruritus associated with chronic kidney disease (CKD) in adults undergoing hemodialysis.
It also develops Oral difelikefalin, which is in Phase II/III clinical trial to treat chronic pruritus with notalgia paresthetica.
The company has license agreements with Maruishi Pharmaceutical Co., Ltd to develop, manufacture, and commercialize drug products containing difelikefalin for acute pain and uremic pruritus in Japan; Vifor Fresenius Medical Care Renal Pharma Ltd. development and commercialization of KORSUVA injection for the treatment of moderate-to-severe pruritus in adult patients undergoing hemodialysis; and Chong Kun Dang Pharmaceutical Corporation to develop, manufacture, and commercialize drug products containing difelikefalin in South Korea.
Cara Therapeutics, Inc. was incorporated in 2004 and is based in Stamford, Connecticut.
| Country | United States |
| Founded | 2004 |
| Industry | Medical - Pharmaceuticals |
| Sector | Healthcare |
| Employees | 55 |
| CEO | Christopher Posner |
Contact Details
Address: 400 Atlantic Street Stamford, Delaware 06901 United States | |
| Phone | 203 406 3700 |
| Website | caratherapeutics.com |
Stock Details
| Ticker Symbol | 0HTC |
| Exchange | London Stock Exchange |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| ISIN Number | US1407551092 |
| SIC Code | 2836 |
Key Executives
| Name | Position |
|---|---|
| Christopher Posner | Chief Executive Officer |
| Ryan Maynard | Chief Financial Officer |